1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  05/23 11:30:53 am EDT
324.50 CHF   +1.50%
05/20Biocon Biologics and Viatris Launch Abevmy (bBevacizumab), Their Third Oncology Biosimilar, in Canada
AQ
05/20Cancer coalition aims to boost access to medicines in poorer countries
RE
05/19ROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ROCHE HOLDINGS AG : Deutsche Bank reiterates its Buy rating

01/11/2022 | 08:23am EDT

In a research note, Deutsche Bank analyst Emmanuel Papadakis has maintained his recommendation on the stock with a Buy rating. The target price remains unchanged at CHF 425.


© MarketScreener with dpa-AFX Analyser 2022
Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION -1.01% 55.89 Delayed Quote.-16.87%
ROCHE HOLDING AG 1.50% 324.5 Delayed Quote.-15.67%
All news about ROCHE HOLDING AG
05/20Biocon Biologics and Viatris Launch Abevmy (bBevacizumab), Their Third Oncology Biosimi..
AQ
05/20Cancer coalition aims to boost access to medicines in poorer countries
RE
05/19ROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
MD
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
05/17AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
MT
05/16TRANSCRIPT : Roche Holding AG - Special Call
CI
05/13PUMP / DUMP #31 : The week's gainers and losers
05/13ROCHE HOLDINGS AG : Reduced to Neutral by Jefferies
MD
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/12ROCHE HOLDINGS AG : Gets a Neutral rating from Morgan Stanley
MD
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 000 M 66 267 M 66 267 M
Net income 2022 14 938 M 15 467 M 15 467 M
Net Debt 2022 10 926 M 11 313 M 11 313 M
P/E ratio 2022 17,2x
Yield 2022 2,99%
Capitalization 264 B 273 B 273 B
EV / Sales 2022 4,29x
EV / Sales 2023 4,12x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 324,50 CHF
Average target price 396,90 CHF
Spread / Average Target 22,3%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-15.67%266 707
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
NOVO NORDISK A/S3.58%245 099